Want to see MGTX full AI Analyst Report?
Top Page
Meiragtx Holdings
(NASDAQ:MGTX)
Select Model
Select Model
Rating:62Neutral
Price Target:
$10.50
▼(-27.88% Downside)
Action:Reiterated
Date:09/23/26
The score is driven primarily by the strong TTM financial inflection, tempered by sustainability risk from historically volatile losses and uneven cash-flow conversion. Technical indicators remain weak (below key moving averages with negative MACD), while valuation is reasonable at ~16x earnings and corporate events are constructive due to significant royalty financing and debt restructuring.
Positive Factors
Revenue and Profitability Inflection
The sharp TTM increase in revenue and return to profitability indicate meaningful commercial progress, while exceptionally high reported margins could support reinvestment and earnings growth. If sustained, this inflection would strengthen the company’s operating position over the next several quarters.
Negative Factors
Unproven Earnings Durability
The recent profit rebound follows several years of heavy losses, making the new earnings profile difficult to regard as established. This history raises the risk that margins and net income could remain volatile, limiting confidence in durable earnings power over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Profitability Inflection
The sharp TTM increase in revenue and return to profitability indicate meaningful commercial progress, while exceptionally high reported margins could support reinvestment and earnings growth. If sustained, this inflection would strengthen the company’s operating position over the next several quarters.
Read all positive factors
Meiragtx Holdings (MGTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$957.55M
Dividend YieldN/A
Average Volume (3M)992.07K
Price to Earnings (P/E)13.0
Beta (1Y)1.67
Revenue Growth948.35%
EPS GrowthN/A
CountryUS
Employees393
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.76
Shares Outstanding96,043,000
10 Day Avg. Volume941,457
30 Day Avg. Volume992,070
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)-110.38
Price to Sales (P/S)7.86
P/FCF Ratio-12.74
Enterprise Value/Market Cap1.29
Enterprise Value/Revenue3.11
Enterprise Value/Gross Profit3.20
Enterprise Value/Ebitda4.71
Forecast
1Y Price Target
$22.40Price Target Upside53.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.31
Revenue Forecast (FY)$337.59M
Meiragtx Holdings Business Overview & Revenue Model
Company Description
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular...
Meiragtx Holdings Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
64
Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 397.50M | 81.39M | 33.28M | 14.02M | 15.92M | 37.70M |
| Gross Profit | 386.34M | 76.55M | 9.49M | 14.02M | 15.92M | 37.70M |
| EBITDA | 262.41M | -89.46M | -121.69M | -57.06M | -116.07M | -71.40M |
| Net Income | 78.98M | -114.20M | -147.79M | -84.03M | -129.62M | -79.56M |
Balance Sheet | ||||||
| Total Assets | 396.45M | 244.43M | 269.75M | 326.74M | 318.24M | 320.16M |
| Cash, Cash Equivalents and Short-Term Investments | 143.17M | 65.93M | 103.66M | 129.57M | 115.52M | 137.70M |
| Total Debt | 112.32M | 88.69M | 84.80M | 89.26M | 92.25M | 23.73M |
| Total Liabilities | 180.67M | 250.22M | 201.92M | 188.57M | 200.50M | 134.76M |
| Stockholders Equity | 215.57M | -5.79M | 67.83M | 138.18M | 117.74M | 185.40M |
Cash Flow | ||||||
| Free Cash Flow | 6.31M | -50.19M | -109.45M | -125.54M | -118.06M | -65.75M |
| Operating Cash Flow | 13.69M | -46.36M | -104.50M | -105.36M | -73.10M | -10.53M |
| Investing Cash Flow | -27.53M | -4.11M | 23.48M | 34.03M | -44.96M | -61.72M |
| Financing Cash Flow | 128.89M | 12.27M | 54.53M | 84.02M | 95.20M | 1.71M |
Meiragtx Holdings Technical Analysis
Negative
14.56
Price Trends
12.25
Negative
12.03
Negative
10.25
Negative
Market Momentum
-0.70
Negative
36.85
Neutral
37.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGTX, the sentiment is Negative. The current price of 14.56 is above the 20-day moving average (MA) of 10.35, above the 50-day MA of 12.25, and above the 200-day MA of 10.25, indicating a bearish trend. The MACD of -0.70 indicates Negative momentum. The RSI at 36.85 is Neutral, neither overbought nor oversold. The STOCH value of 37.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MGTX.
Meiragtx Holdings Risk Analysis
Meiragtx Holdings disclosed 78 risk factors in its most recent earnings report. Meiragtx Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Meiragtx Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $957.55M | 12.97 | 284.38% | ― | 948.35% | ― | |
56 Neutral | $697.18M | -4.64 | -41.33% | ― | 278712.12% | 26.59% | |
53 Neutral | $1.58B | -5.62 | -111.96% | ― | 30.24% | -3.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.34B | -9.75 | -56.19% | ― | -32.27% | -21.09% | |
44 Neutral | $488.50M | -1.89 | -220.07% | ― | 12.00% | -9.21% | |
41 Neutral | $686.24M | -3.36 | -72.28% | ― | ― | 31.81% |
* Healthcare Sector Average
MGTX
Meiragtx Holdings
9.77
1.02
11.66%
QURE
uniQure
23.11
-36.22
-61.05%
RGNX
RegenXBio
7.17
-5.41
-43.00%
SLDB
Solid Biosciences
6.19
0.67
12.14%
TSHA
Taysha Gene Therapies
4.01
-0.94
-18.93%
FDMT
4D Molecular Therapeutics
11.85
1.85
18.50%
Meiragtx Holdings Corporate Events
Business Operations and StrategyExecutive/Board Changes
MeiraGTx Appoints Veteran Investor Alan Sebulsky to Board
Positive
Sep 23, 2026
On September 22, 2026, MeiraGTx’s board appointed veteran healthcare portfolio manager Alan M. Sebulsky as a Class I director, effective September 23, 2026, with his term running until the 2028 annual meeting of shareholders. Sebulsky, who w...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.